Growth-hormone-releasing hormone vs Tesamorelin
The hypothalamic signal that tells the pituitary to release GH. An FDA-approved GHRH analog that selectively trims visceral fat. Side by side: type, evidence tier, receptor, molecular weight, and half-life — the same fields as each monograph, rearranged so the engineering difference is visible.
Growth-hormone-releasing hormone GHRH | Tesamorelin | |
|---|---|---|
| Also known as | — | Egrifta |
| Type | Endogenous | Analog |
| Evidence | Established | Clinical |
| Family | Growth & repair | Growth & repair |
| Class | Hypothalamic releasing peptide (44 aa) | Stabilized GHRH(1-44) analog |
| Receptor | GHRH receptor (GHRHR), a class B GPCR | GHRH receptor (GHRHR), a class B GPCR |
| Molecular weight | ~5,039.6 Da | ≈5,136 Da |
| Half-life | ||
| Based on | Native hormone | Growth-hormone-releasing hormone |
Half-life bars are on a logarithmic scale across the molecules shown. Reference values for the native or representative form — educational only, not medical or dosing advice.
Common questions
- What is the difference between Growth-hormone-releasing hormone and Tesamorelin?
- Growth-hormone-releasing hormone is an endogenous hormone; Tesamorelin is an engineered analog based on Growth-hormone-releasing hormone. Growth-hormone-releasing hormone signals at GHRH receptor (GHRHR), a class B GPCR; Tesamorelin signals at GHRH receptor (GHRHR), a class B GPCR.
- How do the half-lives of GHRH and Tesamorelin compare?
- The reported circulating half-life of Growth-hormone-releasing hormone is ~7–50 min; Tesamorelin is ~26-38 min (subcutaneous). These are reference values for the native or representative form — educational only, not dosing advice.
Prefer the other order? Tesamorelin vs Growth-hormone-releasing hormone. Or open the interactive comparison tool to add more molecules.